Obesity, Diabetes and their Comorbidities: Prevention and Treatment
Lines of Research
01.Intestinal microflora, insulin resistance, and obesity.
02.Role of adipobiology in metabolic diseases.
03.Metabolic effect of bariatric surgery.
04.Environmental factors in the genesis of obesity and diabetes (brown adipose tissue and endocrine disruptors).
05.New celular and molecular mechanisms of inflammation in metabolic diseases: obesity, diabetes, and cancer
06.Genetic and epigenetic factors in the prevention, progression, and treatment of type 2 and gestational diabetes
07.PREDIMED PLUS Study.
08.Dietotherapeutic approach to obesity and cardiovascular disease: role of ketosis, intermittent fasting, physical exercise, and chronobiology.
09.Mitochondrial fitness in metabolic diseases.
10.Endocrine-metabolic complications of obesity
11.Obesity and brain aging.
12.Biomarker analysis of intervention response for weight loss.
13.Immunity in metabolic diseases.
14.Role of pregnancy and breastfeeding in the onset of metabolic diseases.
- Research projects
- Clinical studies
- Scientific Publications
- Technological Offers
- Industrial property records
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
EUthyroid
Towards the elimination of iodine deficiency and preventable thyroid-related diseases in Europe
ABSTRACT
Partners
-
-
- INMA-Valencia group Endocrinology and Nutrition Unit,
- University Regional Hospital of Malaga Andalusian Public Foundation for Health and Biomedicine Research (FIMABIS)
- Hospital Moisès Broggi Spanish Biomedical Research Centre in Diabetes
- Associated Metabolic Disorders (CIBERDEM) IDIAP
- Programma interdipartimentale Nuovi Modelli di gestione multidisciplinare e integrata di Endocrinologia
- University Hospital of Messina University of Turin Department of Cell Biology and Neurosciences
- Istituto Superiore di Sanità
- Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
- Cyprus International Institute for Environmental and Public Health
- Dokuz Eylül University Faculty of Medicine Department of Public Health, Izmir, Turkey
- Republican Specialized Scientific Practical Medical Center of Endocrinology (RSSPMCE), Uzbekistan
- The National Association of Nutritionists of Georgia, Tbilisi, Georgia
- Medical Psychology Dept., Tianjin Medical University, China
- Pontificia Universidad Católica de Chile
- IDIKA (e-government for social security)
- Hellenic Commission for Atomic Energy (EEAE)
- Fund Institute of Public Health Institute for Nuclear Medicine University Clinic for Endocrinology
- Ministry of Education and Science Food and Veterinary Agency
- University Clinic for Pediatrics University Clinic for Gynaecology and Obstetrics
- Institute for Clinical Biochemistry Acibadem Sistina private hospital Agency for Drugs of Macedonia
- Institute of Public Health; Albania
- National Health Insurance Fund of Bulgaria
-
-
-
- Bulgarian National Cancer Registry Tokuda
- Hospital Sofia
- Bulgarian Society of Endocrinology
- National Institute of Endocrinology CI Parhon, Bucharest, Romania
- The Institute of Health Information and Statistics (IHIS) of the Czech Republic
- The Interdisciplinary Committee for Solution of Iodine Deficiency
- Kassenärztliche Vereinigung MV Robert Koch-Institut Berlin Institute of Medical Epidemiology
- Biostatistics, and Informatics
- Martin-Luther-University Halle-Wittenberg
- Halle (Saale)
- Division de la Médecine Scolaire de la Santé des Enfants et des Adolescents
- Intermutualiste Institut national d’assurance maladie-invalidité (INAMI)
- Fondation du Registre du Cancer
- SPF Santé publique, Sécurité de la Chaîne alimentaire et Environnement Agence
- University of Cardiff Northern Ireland Centre for Food and Health (NICHE)
- School of Biomedical Sciences
- Ulster University BHF Centre for Cardiovascular Science
- Queen’s Medical Research Institute Regional Centre for Endocrinology
- Belfast Health and Social Care Trust
- Narodowy Fundusz Zdrowia Ministerstwo Zdrowia RP
- Education Establishment International Sakharov Environmental Institue of Belarusian State University, Minsk, Belarus
- Center for Disease Prevention and Control (CDPC) of Latvia National Health Service
- Norwegian Directorate of Health
-
MID-FRAIL-STUDY
Towards the elimination of iodine deficiency and preventable thyroid-related diseases in Europe
ABSTRACT
FOODBALL
The Food Biomarkers Alliance, FOODBALL
RECOMBINANT SOLUBLE ISOFORM OF THE HUMAN IFNSS RECEPTOR (ISOL) AS A POTENTIAL THERAPEUTIC MOLECULE FOR MULTIPLE SCLEROSIS
RESSTORE
REgenerative Stem cell therapy for STroke in Europe
ABSTRACT
Cost-Effectiveness anaylsys in abdominal aortic aneurysm
CHRODIS-PLUS: Implementing good practices for chronic diseases
Dietary Intervention in Food Allergy: Microbiome, Epigenetic and Metabolomic interactions
ABSTRACT
CHRODIS PLUS is a three-year initiative (2017-2020) funded by the European Commission and participating organisations.
Altogether. 17 policy dialogues and 21 implementation projects form the Action’s core:
The policy dialogues (15 at the national level, and two at the EU level) increase awareness and acceptance in decision-makers in regards to improved actions for combatting chronic diseases.
The pilot projects focus on the following areas: Health Promotion & Primary Prevention, an Integrated Multimorbidity Care Model, Fostering Quality Care for People with Chronic Diseases, ICT-based Patient Empowerment, and Employment & Chronic Diseases
A heavy price for chronic diseases: it has been estimated that chronic diseases cost EU economies €115 billion or 0.8% of GDP annually. Approximately 70% to 80% of health care budgets across the EU are spent on treating chronic diseases.
The EU and chronic diseases: Reducing the burden of chronic diseases such as diabetes, cardiovascular disease, cancer and mental disorders is a priority for EU Member States as well as at the EU Policy level, since chronic diseases affect 8 out of 10 people aged 65 and older in Europe. A wealth of knowledge exists within EU Member States on effective and efficient ways to prevent and manage cardiovascular disease, stroke and type-2 diabetes. Great potential exists for reducing the burden of chronic diseases by using this knowledge more effectively.
The role of CHRODIS PLUS: CHRODIS PLUS, during its 36 months of operation will contribute to the reduction of this burden by promoting the implementation of policies and practices that have been demonstrated to be successful. The development and sharing of these tested policies and projects across EU countries is the core idea behind this action.
The cornerstones of CHRODIS PLUS: This Joint Action raises awareness that in a health-promoting Europe – free of preventable chronic diseases, premature deaths and avoidable disabilities – initiatives in regards to chronic diseases should build on four cornerstones:
health promotion and primary prevention as a way to reduce the burden of chronic diseases patient empowerment tackling functional decline and quality of life as the main consequences of chronic diseases making health systems sustainable and responsive to the ageing of our populations associated with the epidemiological transition.
Partners
-
-
- Federal Public Service Health, Food chain safety and Environment (Coordinator)
- National Center of Public Health and Analyses, Sophia
- Croatian Institute of Public Healt
- The Danish Committee for Health Education
- European Chronic Diseases Association
- European Federation of Neurological Associations
- European Association of Service Providers for Persons with Disabilities
- Flemish Region
- European Brain Council
- EuroHealthNet
- National Institute for Health and Welfare
- Finnish Institute of Occupational Health
- Technical Research Institute Finland
- The French National Cancer Institute
- Technical University of Drezda
- University of Ulm
- Otto von Guericke University Magdeburg
- University Hospital Regensburg
- Aristotle University of Thessaloniki
- Centre for Research and Technology Hellas
- National Oncology Institute
- Semmelweis University
- The Directorate of Health
- Health Service Executive Government Agency
- Institute of Public Health in Ireland Limited
-
-
-
- Foundation IRCCS Carlo Besta Neurological Institute
- Catholic University of the Sacred Heart
- Local Health Services of Turin
- Ministry of Health Italy
- National Institute of Health
- Vilnius University
- The Hospital of Lithuanian University of Health Sciences Kauno Klinikos
- Institute of Hygiene
- Vilnius University Hospital Santaros Klinikos
- European Patients’ Forum
- Ministry for Health, Government of Malta
- National Institute for Health and Environment
- National Institute of Geriatrics, Rheumatology and Rehabilitation
- Ministry of Health of Portugal
- 4Faculty of Medicine, University of Belgrade
- Institute of Public Health of Serbia
- The Ministry of Health of the Slovak Republic
- National Institute of Public Health Slovenia
- Agency for Health Quality and Assessment of Catalonia
- Institute of Health Sciences of Aragon
- International Centre of Excellence in Chronicity Research
- Anadusian Regional Ministry of Health
- Cantabria Health Council
- Institute of Salud Carlos III
-
High-Resolution Plasma Metabolomics for Nutrition-Related Metabolic Assessment in Adults with Cystic Fibrosis
Dietary Intervention in Food Allergy: Microbiome, Epigenetic and Metabolomic interactions
ABSTRACT
Partners
Plantilla Morbius
Cure for Miniature Brittle Bones: Treatment of Osteogenesis ImpeRfecta patient-derived Bone organoids with Innovative AAV-mediated Ultimate Gene-editing System
ABSTRACT
Myocardial infarction (MI) is a leading cause of death worldwide. After MI, long-term antithrombotic therapy is crucial to prevent recurrent events, but increases bleeding, that also impacts morbidity and mortality. Giving these competing risks prediction tools to forecast ischemic and bleeding are of paramount importance to inform clinical decisions, but their current precision is limited.
Improve events prediction, by discovering novel and innovative markers of risk would have a tremendous impact on therapeutic decisions and patients’ outcome. I hypothesize that using innovative multidimensional information from wearable devices, biomarkers, behavioural patterns and non-invasive imaging, integrated through artificial intelligence computation, we may discover novel “computational biomarkers” of risk and improve current standards of risk prediction. In this project, I will enrol a large cohort of MI patients, whereby prospective collection of consolidated and innovative potential risk predictors will take place, in order to
generate a comprehensive and multidimensional dataset. I will collect data from state-of-the-art non-invasive imaging, blood biomarkers, wearable medical devices of continuous heart electrical activity, sweat, mobility and behavioural patterns to create a large physiological time series allowing patients’ deep phenotyping. We will therefore analyze data leveraging artificial intelligence computation to find relevant associations with clinical outcomes, and compare new algorithms with current risk prediction tools.
This research will increase our knowledge on bleeding and ischemic risk factors, enabling enhanced capability predictions models. In the near future, we hypothesize that our clinically-guided Artificial Intelligence algorithm might be integrated in clinical practice, helping clinicians to inform treatment decisions, patients to better understand their risk profile, finally setting a common ground for shared patient/physician decisions.
OBJECTIVES
1. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
2. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Know more about us
MORBIUS
Fellow
Dr. Liidia Zhytnik
Supervisors
Dr. Iván Durán
📩app.oraclemi@gmail.com
Team
- Prof. Andrés Ortiz – Computational Scientist
- Dr. Arancha Diaz Exposito – Investigador Clinico
- Dr. Jorge Rodriguez-Capitan – Investigador Clinico
- Dr. Jose Manuel Garcia Pinilla – Investigador Clinico
- Dr. Cristobal Urbano Carrillo – Investigador Clinico
- Dr. Juan Jose Gomez Doblas – Investigador Clinico
- Prof. Manuel Jimenez-Navarro – Investigador Clinico
Follow our social Networks
Avanzar en la medicina de precisión aplicada a la Neurología: reto de una nueva jornada de la Alianza Andalucía-Roche
IBIMA Plataforma BIONAND ha acogido una jornada de formación celebrada en el marco de la alianza estratégica que mantiene desde final de 2022 la Consejería de Salud y Consumo y Roche Farma España
La Alianza Andalucía-Roche en Neurología Médica de Precisión trabaja en el desarrollo y la aplicación de biomarcadores moleculares y de imagen que permitan ofrecer un abordaje integral y personalizado en enfermedades neurológicas
En el marco de la alianza para el desarrollo de proyectos de investigación en el ámbito de las neurociencias entre la Consejería de Salud y Consumo de la Junta de Andalucía y Roche Farma España, se ha celebrado recientemente una jornada formativa de Medicina Personalizada de Precisión en Neurología, que ha tenido lugar en el centro de investigación malagueño IBIMA Plataforma BIONAND, y acreditada por la Agencia de Calidad Sanitaria de Andalucía.
En esta jornada, en la que han participado una treintena de investigadores e investigadoras vinculados a la Alianza procedentes de diferentes centros sanitarios andaluces, se han expuesto novedades relevantes en el ámbito de la Neurología Médica de Precisión a nivel nacional, destacando la introducción a los conceptos básicos de medicina de precisión y personalizada; su aplicación en enfermedades neurodegenerativas: la farmacogenética aplicada; la inteligencia artificial vinculada a los resultados en salud; la actualización de conceptos de biología molecular y desarrollo de biomarcadores; la genética clínica y molecular en enfermedades neurológicas; o, específicamente, las epilepsias de base genética.
La jornada ha servido también para poner en común estrategias y resultados de los diferentes grupos que la componen, así como para conocer de primera mano las instalaciones e infraestructuras del centro malagueño. En concreto, se ha destacado la visita al SIMOA, una infraestructura tecnológica de última generación adquirida en el marco de la Alianza. Este analizador ultrasensible permitirá la detección de biomarcadores de una forma más precisa, suponiendo un importante avance en la detección precoz de enfermedades neurológicas y en su conocimiento. Este servicio científico-técnico está disponible para cualquier miembro de la comunidad científica.
Alianza Andalucía-Roche de Neurología Médica de Precisión
La Alianza Andalucía-Roche de Neurología Médica de Precisión nació a final de 2022 con el fin de desarrollar proyectos de investigación que permitan implantar la medicina personalizada en el ámbito de la neurología. Para ello impulsa el desarrollo y la aplicación de biomarcadores moleculares y de imagen que permitan ofrecer un abordaje integral y personalizado, una línea de trabajo que ya está en marcha y ha conseguido movilizar hasta el momento inversiones de en torno a un millón de euros.
Además, tiene el objetivo de definir un programa científico en Neurología Médica de Precisión que profundice en el conocimiento de las enfermedades neurológicas, contando para ello con profesionales de referencia de la sanidad pública andaluza, a los que se sumarán jóvenes investigadores, en un proyecto que nace con vocación de continuidad gracias a la colaboración público-privada.
La Alianza Andalucía-Roche de Neurología Médica de Precisión es una iniciativa público-privada cuya actividad científica estará liderada por el coordinador de la NeuroReca, Pedro Serrano, jefe de la Unidad de Neurología del Hospital Regional de Málaga.
En esta alianza participa en estos momentos una veintena de profesionales en neurociencias, tanto del ámbito de la investigación como de la asistencia, procedentes de distintas provincias de Andalucía.
Los proyectos e iniciativas que se desarrollen en el marco de esta alianza se vertebrarán a través de la NeuroReca, la Red Andaluza de Investigación Clínica y Traslacional en Neurología, optimizando así las sinergias que ya existen en el seno del Sistema Sanitario Público de Andalucía.
An overview of vitamins as epidrugs for colorectal cancer prevention – NUTRITION REVIEWS
Boughanem, H; Kompella, P; Tinahones, FJ; Macias-Gonzalez, M – 2023 – 10.1093/nutrit/nuac065
Development of a food composition database of different food contaminants CONT11 and estimation of dietary exposure in children of southern Spain – FOOD AND CHEMICAL TOXICOLOGY
Hinojosa-Nogueira, D; Muros, JJ; Navajas-Porras, B; Delgado-Osorio, A; Pérez-Burillo, S; Pastoriza, S; Rufián-Henares, JA – 2023 – 10.1016/j.fct.2023.113843
Glycaemic and insulinaemic impact of a diabetes-specific oral nutritional supplement with extra-virgin olive oil in patients with type 2 diabetes mellitus at nutritional risk: a randomized, double-blind, crossover, multicentre clinical trial (DIACARE). – NUTRICION HOSPITALARIA
Garcia Almeida, Jose Manuel; Vegas Aguilar, Isabel Maria; Calleja Fernandez, Alicia; Porca Fernandez, Cristina; Casanas Quintana, Tamara; Tejera Perez, Cristina; Tinahones Madueno, Francisco Jose; Bellido Guerrero, Diego – 2023 – 10.20960/nh.04577
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly – CLINICAL ENDOCRINOLOGY
Ruiz, S; Gil, J; Biagetti, B; Venegas, E; Camara, R; Garcia-Centeno, R; Galvez, MA; Pico, A; Maraver, S; Gonzalez, I; Abellan, P; Trincado, P; Herrera, M; Olvera, P; Xifra, G; Bernabeu, I; Serra-Soler, G; Azriel, S; Garcia, L; Carvalho, D; Jordà, M; Valassi, E; Puig, J; Puig-Domingo, M – 2023 – 10.1111/cen.14946
Phase angle as a marker of outcome in hospitalized pediatric patients. A systematic review of the evidence (GRADE) with meta-analysis. – REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
Fernandez-Jimenez, R; Martin-Masot, R; Cornejo-Pareja, I; Vegas-Aguilar, IM; Herrador-Lopez, M; Tinahones, FJ; Navas-Lopez, VM; Bellido-Guerrero, D; Garcia-Almeida, JM – 2023 – 10.1007/s11154-023-09817-1
Ultra-processed foods consumption as a promoting factor of greenhouse gas emissions, water, energy, and land use: A longitudinal assessment. – SCIENCE OF THE TOTAL ENVIRONMENT
Garcia, S; Pastor, R; Monserrat-Mesquida, M; Alvarez-Alvarez, L; Rubin-Garcia, M; Martinez-Gonzalez, MA; Salas-Salvado, J; Corella, D; Fito, M; Martinez, JA; Tojal-Sierra, L; Warnberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Santos-Lozano, JM; Serra-Majem, L; Cano-Ibanez, N; Pinto, X; Delgado-Rodriguez, M; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Buil-Cosiales, P; Martinez-Rodriguez, MA; Coltell, O; Castaner, O; Garcia-Rios, A; Barcelo, C; Gomez-Gracia, E; Zulet, MA; Konieczna, J; Casas, R; Masso-Guijarro, P; Goicolea-Guemez, L; Bernal-Lopez, MR; Bes-Rastrollo, M; Shyam, S; Gonzalez, JI; Zomeno, MD; Pena-Orihuela, PJ; Gonzalez-Palacios, S; Toledo, E; Khoury, N; Perez, KA; Martin-Sanchez, V; Tur, JA; Bouzas, C – 2023 – 10.1016/j.scitotenv.2023.164417
Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort. – BMC MEDICINE
Shyam, S; Garcia-Gavilan, JF; Paz-Graniel, I; Gaforio, JJ; Martinez-Gonzalez, MA; Corella, D; Martinez, JA; Alonso-Gomez, AM; Waernberg, J; Vioque, J; Romaguera, D; Lopez-Miranda, J; Estruch, R; Tinahones, FJ; Lapetra, J; Serra-Majem, JL; Bueno-Cavanillas, A; Tur, JA; Sanchez, VM; Pinto, X; Matia-Martin, P; Vidal, J; Vazquez, C; Daimiel, L; Ros, E; Fernandez-Aranda, F; Nishi, SK; Garcia-Regata, O; Toledo, E; Asensio, EM; Castaner, O; Garcia-Rios, A; Torres-Collado, L; Gomez-Gracia, E; Zulet, MA; Ruiz, NG; Casas, R; Cano-Ibanez, N; Tojal-Sierra, L; Gomez-Perez, AM; Sorli, JV; Cinza-Sanjurjo, S; Martin-Pelaez, S; Pena-Orihuela, PJ; Oncina-Canovas, A; Perez-Araluce, R; Zomeno, MD; Chaplin, A; Delgado-Rodriguez, M; Babio, N; Fito, M; Salas-Salvado, J – 2023 – 10.1186/s12916-023-03079-z
Dietary diversity and depression: cross-sectional and longitudinal analyses in Spanish adult population with metabolic syndrome. Findings from PREDIMED-Plus trial, – PUBLIC HEALTH NUTRITION
Cano-Ibáñez, N; Serra-Majem, L; Martín-Peláez, S; Martínez-González, MA; Salas-Salvadó, J; Corella, D; Lassale, C; Martínez, JA; Alonso-Gómez, AM; Wärnberg, J; Vioque, J; Romaguera, D; López-Miranda, J; Estruch, R; Gómez-Pérez, AM; Lapetra, J; Fernández-Aranda, F; Bueno-Cavanillas, A; Tur, JA; Cubelos, N; Pintó, X; Gaforio, JJ; Matía-Martín, P; Vidal, J; Calderón, C; Daimiel, L; Ros, E; Gea, A; Babio, N; Gimenez-Alba, IM; Zomeño-Fajardo, MD; Abete, I; Sierra, LT; Romero-Galisteo, RP; de la Hera, MG; Martín-Padillo, M; García-Ríos, A; Casas, RM; Fernández-García, JC; Santos-Lozano, JM; Toledo, E; Becerra-Tomas, N; Sorli, J; Schröder, H; Zulet, MA; Sorto-Sánchez, C; Diez-Espino, J; Gómez-Martínez, C; Fitó, M; Sánchez-Villegas, A – 2023 – 10.1017/S1368980022001525
Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis. – GUT MICROBES
Gomez-Perez, AM; Ruiz-Limon, P; Salas-Salvado, J; Vioque, J; Corella, D; Fito, M; Vidal, J; Atzeni, A; Torres-Collado, L; Alvarez-Sala, A; Martinez, MA; Goday, A; Benaiges, D; Garcia-Gavilan, J; Lopez, MRB; Moreno-Indias, I; Tinahones, FJ – 2023 – 10.1080/19490976.2023.2223339
Management of thyroid dysfunction and thyroid nodules in the ageing patient. – EUROPEAN JOURNAL OF INTERNAL MEDICINE
Martinez-Montoro, Jose Ignacio; Doulatram-Gamgaram, Viyey Kishore; Olveira, Gabriel; Valdes, Sergio; Fernandez-Garcia, Jose Carlos – 2023 – 10.1016/j.ejim.2023.06.005
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Members
-
Researcher in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
Francisco José Tinahones Madueño
-
Co-investigator in ChargeSerá Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigación del Instituto y sus Co-IR. Esta categoría puede incluir investigadores muy excepcionales en su disciplina.
Manuel Macías González
Isabel Moreno Indias
-
Senior InvestigatorSerán aquellos que tengan una actividad investigadora de al menos 5 años en la etapa posdoctoral. Estos investigadores estarán adscritos a un Grupo de Investigación liderado por un Investigador Responsable. Las funciones serán las que le tenga asignadas su IR.
Pueden liderar una línea de investigación de alguno de los grupos de investigación del Instituto, con financiación competitiva propia, y con potencial para llegar a convertirse responsable de un grupo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Collaborating Healthcare ResearcherSerá Investigador Asistencial Colaborador el Investigador que no reúne la consideración de Investigador Posdoctoral. Estarán adscritos a un Grupo de Investigación liderado por un IR. Las funciones serán las que le tenga asignada su IR.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Postdoctoral and/or junior researchersEsta etapa posdoctoral estará restringida a Investigadores del Instituto que tengan el título doctor y no contemplados en los perfiles posteriores. Durante su etapa posdoctoral pueden llegar a liderar proyectos de I+D+i como Investigadores Principales, aunque aún no hayan establecido un nivel significativo de independencia. Además, pueden tener actividades de docencia y/o asistencial más allá de su trabajo de investigación.
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Predoctoral and/or Training Researchers
Los investigadores predoctorales y/o en formación serán aquellos investigadores que realizan investigaciones bajo supervisión en una línea de investigación orientada a la resolución de problemas de salud. Incluye aquellos investigadores que están cursando un doctorado (incluyendo a los contratados Río Hortega)
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
-
Technical staff
Los investigadores predoctorales y/o en formación serán aquellos investigadores que realizan investigaciones bajo supervisión en una línea de investigación orientada a la resolución de problemas de salud. Incluye aquellos investigadores que están cursando un doctorado (incluyendo a los contratados Río Hortega)
No results
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.